108 results
Page 3 of 6
8-K
EX-99.1
bhl63fe5md6hy99
3 Nov 21
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business
7:10am
8-K
EX-99.1
io62krd 9r
5 Aug 21
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
7:11am
8-K
EX-99.1
6yepy
3 May 21
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
7:20am
8-K
EX-99.1
1e2ax
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
bzdp qh72zgit
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
dbfsuq3p2c3o
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.1
pn6 zway9jvt23cq
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
s0jdqpp6
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
nfdtxw
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
v2uax5s1n2ubmsafi
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
8-K
EX-99.1
ie2xevipin82cq1jv1
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
8-K
EX-1.1
3jw nnd095mbb
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm